Previous studies suggested that PBRM1 mutation enhances the sensitivity of tumor cells to immunotherapeutic drugs and hence can be used as a new biomarker to evaluate the effectiveness of immunotherapy.12, 13. Here, PBRM1 is linked to neoplasm.